Pfizer mCRC Program Update Clinical Development Plan 2023

Pfizer presents an update on its metastatic colorectal cancer (mCRC) program and clinical development strategy. The company outlines expectations for clinical data from its first-line RAS-mutated mCRC trial, anticipated in mid-2024. This investor presentation details progress in oncology pipeline development and therapeutic advancement.